ストックスクリーナーアプリを入手
69.41
2.10%
1.43
アフターアワーズ：
69.41
前日終値:
$67.98
開ける：
$68.81
24時間の取引高:
1.81M
Relative Volume:
0.65
時価総額：
$13.46B
収益：
$502.08M
当期純損益:
$-732.94M
株価収益率:
-18.34
EPS:
-3.7842
ネットキャッシュフロー:
$-455.50M
1週間 パフォーマンス:
+6.20%
1か月 パフォーマンス:
-7.76%
6か月 パフォーマンス:
+35.54%
1年 パフォーマンス:
+114.83%
1日の値動き範囲:
$67.73
$70.00
1週間の範囲:
$64.50
$75.91
52週間の値動き範囲:
$28.32
$84.94
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Compare BBIO vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
69.41 | 13.46B | 502.08M | -732.94M | -455.50M | -3.7842 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-10 | 開始されました | William Blair | Outperform |
| 2026-01-28 | 開始されました | Barclays | Overweight |
| 2026-01-06 | 開始されました | Morgan Stanley | Overweight |
| 2025-12-11 | 開始されました | Bernstein | Outperform |
| 2025-07-30 | 再開されました | Raymond James | Outperform |
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-07-14 | 開始されました | Jefferies | Buy |
| 2025-07-09 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-06-17 | 開始されました | Wolfe Research | Outperform |
| 2025-03-31 | 開始されました | Redburn Atlantic | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-10-03 | 開始されました | Oppenheimer | Perform |
| 2024-09-04 | 開始されました | Piper Sandler | Overweight |
| 2024-03-21 | 再開されました | Raymond James | Outperform |
| 2024-01-31 | 開始されました | BMO Capital Markets | Market Perform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-11-07 | 開始されました | Citigroup | Buy |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-07-18 | ダウングレード | Jefferies | Buy → Hold |
| 2023-04-19 | 開始されました | Evercore ISI | Outperform |
| 2023-02-06 | 開始されました | Cowen | Outperform |
| 2021-12-27 | 繰り返されました | Mizuho | Buy |
| 2021-12-27 | 繰り返されました | SVB Leerink | Outperform |
| 2021-09-10 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-03-22 | 繰り返されました | Goldman | Buy |
| 2021-02-22 | 再開されました | JP Morgan | Overweight |
| 2021-02-09 | 再開されました | Goldman | Buy |
| 2021-01-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-10 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-25 | 開始されました | BofA/Merrill | Neutral |
| 2020-05-19 | 開始されました | BTIG Research | Buy |
| 2020-04-13 | 開始されました | H.C. Wainwright | Buy |
| 2020-02-19 | 開始されました | Mizuho | Buy |
| 2019-07-26 | 開始されました | Raymond James | Outperform |
| 2019-07-22 | 開始されました | BMO Capital Markets | Outperform |
| 2019-07-22 | 開始されました | Goldman | Buy |
| 2019-07-22 | 開始されました | JP Morgan | Overweight |
| 2019-07-22 | 開始されました | Jefferies | Buy |
| 2019-07-22 | 開始されました | Piper Jaffray | Overweight |
| 2019-07-22 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Bridgebio Pharma Inc (BBIO) 最新ニュース
A Look At BridgeBio Pharma (BBIO) Valuation After Strong Long Term Returns And Recent Share Pullback - Yahoo Finance
The week in pharma: action, reaction and insight – week to March 13, 2026 - The Pharma Letter
Boone Capital Management LLC Buys Shares of 460,282 BridgeBio Pharma, Inc. $BBIO - MarketBeat
Prosight Management LP Sells 208,187 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
How Positive Phase 3 LGMD Data Could Shape BridgeBio Pharma’s (BBIO) Risk Profile and Upside Potential - simplywall.st
BridgeBio Touts Attruby Uptake, Bayer's Europe Rollout, and Pipeline Timelines - National Today
BridgeBio Pharma Touts Attruby Uptake, Bayer’s Europe Rollout and 2026-28 Pipeline Timelines at Leerink Conf - MarketBeat
BridgeBio Pharma CEO Teases Pipeline Launches, Attruby Momentum, and Pfizer Tafamidis Trial Update - Yahoo Finance
BridgeBio Looks At Genetic Testing To Build Out BBP-418 Launch In LGMD2I/R9 - Citeline News & Insights
A Look At BridgeBio Pharma (BBIO) Valuation After Recent Share Price Volatility - simplywall.st
BridgeBio reports Phase III progress for BBP-418 - The Pharmaletter
BridgeBio Pharma Eyes First Treatment For Rare Muscle Disorder As Trial Data Shows Early Progress - Benzinga
Barclays Maintains Overweight on BridgeBio Pharma (BBIO) March 2026 - Meyka
Capital Research Global Investors Sells 2,055,172 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
Leerink Maintains Outperform on BBIO, BridgeBio Pharma, Inc. March 12, 2026 - Meyka
BridgeBio (BBIO) Reports Promising Phase 3 Data for BBP-418 in M - GuruFocus
BridgeBio Pharma Presents Promising Phase 3 FORTIFY Interim Analysis Results for BBP-418 in LGMD2I/R9 at MDA Conference - Quiver Quantitative
BridgeBio Pharma plans to submit NDA for BBP-418 to FDA in H1 2026 - marketscreener.com
Bridgebio Pharma Plans To Submit NDA For BBP-418 To FDA In H1 2026 - TradingView
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9 - Yahoo Finance
BridgeBio (BBIO) Reports Wider Q4 Loss of $1/Share vs $0.63 Estimate; Stock Surges 13% - AlphaStreet
HC Wainwright Raises Earnings Estimates for BridgeBio Pharma - MarketBeat
BridgeBio (BBIO) Sees Price Target Boost and Earns Overweight Ra - GuruFocus
BridgeBio (BBIO) Soars 13% on Double-Digit Price Target Upgrade - Insider Monkey
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for BridgeBio Pharma (NASDAQ:BBIO) Stock - MarketBeat
U.S. Indexes Finished Mixed Tuesday As BridgeBio Pharma Led, Centene Lagged - Barron's
Valantine plans option-based sale; prior 25,484 shares sold (BBIO) - Stock Titan
Barclays reiterates Overweight on BridgeBio Pharma stock By Investing.com - Investing.com Canada
BridgeBio’s Price Target Boost Sparks Investor Excitement - StocksToTrade
Why Is BridgeBio Pharma Stock Soaring Tuesday?BridgeBio Pharma (NASDAQ:BBIO) - Benzinga
JP Morgan Raises Price Target for BridgeBio Pharma (BBIO) to $94 - GuruFocus
BridgeBio Pharma (NASDAQ:BBIO) Trading Up 9.3%Should You Buy? - MarketBeat
BridgeBio Pharma shares jump as investors focus on fresh BBP-418 data at MDA meeting and near-term regulatory milestones - Quiver Quantitative
BridgeBio Pharma’s Surge: A Closer Look at Market Dynamics - StocksToTrade
BridgeBio Pharma’s Growth Momentum Backed by Analyst Confidence - timothysykes.com
BridgeBio Pharma Jumps as Wall Street Piles In - TipRanks
William Blair initiates BridgeBio stock with outperform rating - Investing.com India
William Blair initiates BridgeBio stock with outperform rating By Investing.com - Investing.com South Africa
BridgeBio Pharma (NASDAQ:BBIO) Now Covered by Analysts at William Blair - MarketBeat
FY2027 Earnings Estimate for BBIO Issued By HC Wainwright - MarketBeat
Victory Capital Management Inc. Purchases 141,800 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
BBIO6336503 Bond Analysis — Key Metrics - TradingView
BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz - Bitget
Does Positive Phase 3 BBP-418 Data in LGMD2I/R9 Change The Bull Case For BridgeBio Pharma (BBIO)? - Yahoo Finance
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
How The BridgeBio Pharma (BBIO) Narrative Is Shifting With Attruby And Late Stage Pipeline - Yahoo Finance
Andrea Ellis Sells 64,921 Shares of BridgeBio Pharma (NASDAQ:BBIO) Stock - MarketBeat
BridgeBio Pharma director Ellis Andrea sells $4.2m in shares - Investing.com South Africa
BridgeBio Pharma director Ellis Andrea sells $4.2m in shares By Investing.com - Investing.com UK
BridgeBio Pharma (BBIO) achieves record 2025 revenue driven by Attruby commercial success - MSN
Truist Raises Its Price Target on BridgeBio Pharma, Inc. (BBIO) to $95 and Maintains a Buy Rating - Finviz
Bridgebio Pharma Inc (BBIO) 財務データ
収益
当期純利益
現金流量
EPS
0.48%
1.21%
大文字化:
|
ボリューム (24 時間):